World Bispecific Summit US 2026

Jared Shadish is a senior scientist in the Protein Engineering and Novel Modalities group at AstraZeneca. His work is focused on developing platforms for the efficient development and screening of multispecific antibodies. Jared received his B.S. in Chemical Engineering at Rensselaer Polytechnic Institute, and his Ph.D. at the University of Washington where he developed techniques to enable the spatiotemporal control of protein presentation in biomaterials. Prior to working at AstraZeneca, Jared was a Postdoc at the National Institutes of Health where he studied the biophysical mechanisms of amyloid formation.

Tatiana Novobrantseva is the Chief Scientific Officer at NextPoint Therapeutics. Most recently she served as the CSO of Immuno-oncology at Moderna. In the prior role, she co-founded Verseau Therapeutics and served as CSO, guiding programs from target identification to an advanced novel therapeutics pipeline. Tatiana also consulted on drug development program for various companies throughout the years. At Jounce, she directed programs on immune system reactivation against cancer. Tatiana held roles at Alnylam and Biogen, uncovering the critical role of B cells in fibrosis, advancing siRNA delivery, and leading a dendritic cell cancer vaccine initiative. She earned her Ph.D. in B cell immunology from the University of Cologne in Germany in the Laboratory of Klaus Rajewsky. She holds a Diploma in Engineering in Physics and a Master’s degree in Molecular Biology from the Moscow Institute of Physics and Technology.